ERBB2 and neoplasm: Furthermore, SVs at splicing regions, her2 polymorphisms, or mutations in introns may be originating different isoforms of the protein, triggering the HER2 activity and tumor aggressiveness [38] or therapy resistance [48,49], as has already been described in HBC patients.